SLS
NASDAQ · Biotechnology
Sellas Life Sciences Group I
$10.01
-0.28 (-2.72%)
Open$10.37
Previous Close$10.29
Day High$10.54
Day Low$9.87
52W High$15.88
52W Low$1.39
Volume—
Avg Volume6.25M
Market Cap2.22B
P/E Ratio—
EPS$-0.23
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+238.7% upside
Current
$10.01
$10.01
Target
$33.90
$33.90
$25.20
$33.90 avg
$43.49
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 353.66M | 369.01M | 305.89M |
| Net Income | 19.39M | 21.88M | 20.34M |
| Profit Margin | 5.5% | 5.9% | 6.7% |
| EBITDA | 24.66M | 25.78M | 21.04M |
| Free Cash Flow | 20.13M | 23.20M | 18.29M |
| Rev Growth | -7.4% | -1.2% | +17.7% |
| Debt/Equity | 0.38 | 0.40 | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |